Migraine DisorderHYlaMINCT07644299
Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study
A study testing HYlaMI (Self-Hypnosis Training for Migraine Management) in people with Migraine Disorder, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
Trial summary
Migraine is one of the most common and disabling neurological conditions worldwide, affecting approximately 1 billion people. Available pharmacological treatments have significant limitations (side effects, contraindications, medication overuse), highlighting the need for effective non-pharmacological alternatives. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Migraine Disorder
- What is being tested?
- HYlaMI (Self-Hypnosis Training for Migraine Management)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 1 Jun 2026to 30 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Formal diagnosis of migraine for more than one year (physician-issued; self-reported diagnosis accepted)
- French-speaking
- No consumption of alcohol or recreational drugs on the morning before group hypnosis sessions (migraine rescue medication is accepted but must be reported if taken before a session)
- Reliable internet connection
- Available to follow the 2.5-month self-hypnosis training program
Who cannot join
- Sensory or cognitive impairments that would interfere with comprehension (e.g., deafness)
- Severe, unstabilized neurological or psychiatric disorder that impairs communication
- Previous psychological treatment using hypnosis techniques for pain management
- Current participation in another psychological intervention (potential confounder for anxiety/depression outcomes)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR)
Montreal, Quebec, H1T 2M4
David Ogez, PhD, 514 252-3400 ext. 4443, david.ogez@umontreal.ca
About this study
Official title: Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study of the Intervention Program (ORBIT Phase IIa-IIb)
Migraine is one of the most common and disabling neurological conditions worldwide, affecting approximately 1 billion people. Available pharmacological treatments have significant limitations (side effects, contraindications, medication overuse), highlighting the need for effective non-pharmacological alternatives.
The HYlaMI program (Self-Hypnosis Training for Migraine Management) is an 8-session group-based telehealth intervention adapted from HYlaDO, a self-hypnosis program developed for chronic pain management at the Hôpital Maisonneuve-Rosemont Pain Clinic (Montréal, Canada). Building on a refinement study conducted in autumn 2025 (CER: 2026-4061), HYlaMI combines heterohypnosis (guided by a trained clinician) and self-hypnosis (practiced autonomously at home using audio recordings) through weekly one-hour video sessions (Zoom/CIUSSS EMTL platform).
Read more
This study combines ORBIT Phase IIa (proof of concept) and Phase IIb (pilot study) objectives. The primary aims are to evaluate the feasibility of the HYlaMI program (retention and adherence rates) and to assess whether it can generate a clinically significant change in migraine-related disability compared to a waitlist control group. Secondary aims include evaluating effects on anxiety and depressive symptoms, pain self-efficacy, situational pain/anxiety/relaxation, migraine frequency, intensity and duration, medication intake, work absenteeism, quality of life, and the economic burden of migraine.
A mixed-methods design will be used. Forty adults with a diagnosis of migraine for more than one year will be randomized to either the HYlaMI intervention group (n=20) or a waitlist control group (n=20). Participants will complete validated questionnaires at multiple time points (pre-intervention, mid-intervention, post-intervention, and 4-week follow-up), a weekly migraine diary, and self-hypnosis practice logs. Two semi-structured focus groups will be conducted with intervention group participants to inform program improvement.
If successful, this study will provide the evidence base required to proceed to a larger randomized controlled trial (ORBIT Phase III).
Read the detailed description
Background.
Migraine affects approximately 1.04 billion individuals worldwide and is associated with substantial socioeconomic burdens, including reduced quality of life, mental health comorbidities (anxiety, depression), and productivity losses. Non-pharmacological interventions, including clinical hypnosis, represent a growing area of investigation.
Intervention.
The HYlaMI program consists of 8 weekly one-hour group sessions delivered via teleconference (Zoom, CIUSSS EMTL platform). Seven hypnotic exercises are introduced sequentially, each following a standard hypnotic structure (induction, deepening, hypnotic work, post-hypnotic suggestions, return to waking state):
- Session 1: Psychoeducation on medical hypnosis and pain + "Pleasant place" exercise
- Session 2: "Backpack" exercise (anxiety and emotion management)
- Session 3: "Doing nothing" exercise (pain acceptance, catastrophizing)
- Session 4: "Thermal object" exercise (pain perception modification)
- Session 5: "Magic hand" exercise (analgesic suggestion)
- Session 6: "Rossi method" (resource-based pain relief)
- Session 7: "Reconnecting with a resource" (introspection and self-efficacy)
- Session 8: Conclusion, self-hypnosis prescription and 30 minutes Focus group on Social Validity of the intervention
A 9th session (1h-Focus group on Self-hypnosis practice+ follow-up meeting) is held 4 weeks post-intervention.
All 7 hypnotic exercises are provided as high-quality audio recordings to enable home self-hypnosis practice between sessions.
Study Design
Mixed-methods pilot and proof-of-concept study with two parallel arms: HYlaMI intervention group and waitlist control group. Randomization is performed using an online random group generator. For ethical reasons, waitlist participants will receive the full intervention after study completion.
Outcome Assessment Schedule
14 measurement time points are planned: T-1 and T0 (pre-intervention baseline), T1-T8 (weekly during intervention), and T9-T12 (weekly post-intervention follow-up).
Hypnotizability
Baseline hypnotizability is assessed using the Harvard Group Scale of Hypnotic Susceptibility, Form A (HGSHS:A), French online version, and will be used as a covariate in all analyses.
Data Management
Electronic questionnaires are managed via REDCap (CIUSSS EMTL server). Paper journals are used for in-session measures. Focus groups are recorded via Zoom, transcribed using OneDrive Word, and analyzed with NVivo 12.
- Conditions
- Migraine Disorder
- Being tested
- HYlaMI (Self-Hypnosis Training for Migraine Management)
- Keywords
- migraine, self-hypnosis, clinical hypnosis, chronic pain, non-pharmacological intervention, telehealth, pain self-efficacy, pilot study, proof of concept, group intervention
- Medical subject headings
- Migraine Disorders, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HYlaMI (Self-Hypnosis Training for Migraine Management)Behavioural
Also called Self-hypnosis training; autohypnosis; HYlaDO adaptation for migraine
Eight weekly one-hour group telehealth sessions (Zoom/CIUSSS EMTL platform) delivering 7 complementary self-hypnosis exercises targeting migraine-related pain, stress, anxiety, and psychological resources. Each session follows a standardized hypnotic structure. High-quality audio recordings of all exercises are provided to participants for home self-hypnosis practice. A clinician-researcher (doctoral candidate in neuropsychology, trained in hypnosis) leads all sessions using a standardized clinician manual. A concluding focus group and follow-up session is held 4 weeks post-intervention.
| Study group | Role | What they receive |
|---|---|---|
| Waitlist control group | No intervention | Participants assigned to the waitlist control group do not receive the HYlaMI intervention during the study period. They complete the same electronic questionnaires and weekly migraine diaries as the intervention group. For ethical reasons, they will receive the full HYlaMI intervention after study completion. |
| HYlaMI Intervention Group | Experimental | Participants assigned to the HYlaMI group attend 8 weekly group telehealth sessions and practice self-hypnosis at home using provided audio recordings. They complete paper journals (in-session EVA ratings and qualitative feedback), weekly electronic migraine diaries, weekly self-hypnosis practice logs, and all standardized questionnaires at designated time points. They participate in two semi-structured focus groups (T8 and T12). Receives: Behavioral: HYlaMI (Self-Hypnosis Training for Migraine Management) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Migraine-related disability - Migraine Disability Assessment (MIDAS)
5-item scale quantifying the number of days affected by migraine in the past 3 months, generating a disability grade (I-IV). Clinically significant improvement defined as a reduction of ≥5 points (grade III, initial score 11-20) or ≥30% (grade IV, initial score >20), per American Headache Society (2019) criteria.
Measured: One-week-pre-intervention (T0) and 4-week post-intervention follow-up (4-weeks-post-intervention: T12)
Migraine-related disability - Headache Impact Test (HIT-6)
6-item scale (score range 36-78) assessing headache impact on daily functioning. Clinically significant improvement defined as a reduction of ≥5 points, per American Headache Society (2019) criteria.
Measured: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Program feasibility - Retention and adherence rates
Descriptive analysis of session attendance (target: ≥6/8 sessions) and attrition rate (target: ≤15%), based on the HYlaDO pilot study.
Measured: Throughout intervention (first to 8th week of intervention: T1-T8)
Secondary outcomes (13)
Anxiety and depressive symptoms
Hospital Anxiety and Depression Scale (HADS)
Measured: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Pain self-efficacy
Pain Self-Efficacy Questionnaire (PSEQ)
Measured: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Situational pain
Visual Analog Scale (VAS), 0-10
Measured: Before and after each hypnosis session (First to 7th week of intervention : T1-T7)
Situational anxiety
Visual Analog Scale (VAS), 0-10
Measured: Before and after each hypnosis session (First to 7th week of intervention : T1-T7)
Situational relaxation
Visual Analog Scale (VAS), 0-10
Measured: Before and after each hypnosis session (First to 7th week of intervention: T1-T7)
Migraine frequency
Weekly migraine diary (number of migraine days per week)
Measured: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12 )
Measure: Migraine intensity
Weekly migraine diary (average intensity, 0-10)
Measured: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Migraine duration
Weekly migraine diary (duration in minutes)
Measured: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Medication intake
Weekly migraine diary (type, dose, number of tablets)
Measured: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Work/school absenteeism
Weekly migraine diary (number of absent days)
Measured: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Quality of life economics
EQ-5D (5 dimensions + VAS, score 0-1 and 0-100)
Measured: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Economic burden of migraine
Cost in health questionnaire (direct and indirect costs)
Measured: 6th week of intervention and 4-weeks-post-intervention follow-up (T6, T12)
Program improvement
Qualitative thematic analysis of two semi-structured focus groups
Measured: T8 (end of intervention) and T12 (4-week follow-up)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Migraine DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David Ogez, Ciusss de L'Est de l'Île de Montréal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07644299
- Sponsor's protocol ID
- CEMTL 2026 4353
- Acronym
- HYlaMI
- Status last verified
- Jun 2026
- First submitted
- 12 May 2026
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study of the Intervention Program (ORBIT Phase IIa-IIb)
- ClinicalTrials.gov ID
- NCT07644299
- Acronym / sponsor ID
- HYlaMI / CEMTL 2026 4353
- Conditions
- Migraine Disorder
- Keywords
- migraine, self-hypnosis, clinical hypnosis, chronic pain, non-pharmacological intervention, telehealth, pain self-efficacy, pilot study
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Ciusss de L'Est de l'Île de MontréalUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 12 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Migraine is one of the most common and disabling neurological conditions worldwide, affecting approximately 1 billion people. Available pharmacological treatments have significant limitations (side effects, contraindications, medication overuse), highlighting the need for effective non-pharmacological alternatives.
The HYlaMI program (Self-Hypnosis Training for Migraine Management) is an 8-session group-based telehealth intervention adapted from HYlaDO, a self-hypnosis program developed for chronic pain management at the Hôpital Maisonneuve-Rosemont Pain Clinic (Montréal, Canada). Building on a refinement study conducted in autumn 2025 (CER: 2026-4061), HYlaMI combines heterohypnosis (guided by a trained clinician) and self-hypnosis (practiced autonomously at home using audio recordings) through weekly one-hour video sessions (Zoom/CIUSSS EMTL platform).
This study combines ORBIT Phase IIa (proof of concept) and Phase IIb (pilot study) objectives. The primary aims are to evaluate the feasibility of the HYlaMI program (retention and adherence rates) and to assess whether it can generate a clinically significant change in migraine-related disability compared to a waitlist control group. Secondary aims include evaluating effects on anxiety and depressive symptoms, pain self-efficacy, situational pain/anxiety/relaxation, migraine frequency, intensity and duration, medication intake, work absenteeism, quality of life, and the economic burden of migraine.
A mixed-methods design will be used. Forty adults with a diagnosis of migraine for more than one year will be randomized to either the HYlaMI intervention group (n=20) or a waitlist control group (n=20). Participants will complete validated questionnaires at multiple time points (pre-intervention, mid-intervention, post-intervention, and 4-week follow-up), a weekly migraine diary, and self-hypnosis practice logs. Two semi-structured focus groups will be conducted with intervention group participants to inform program improvement.
If successful, this study will provide the evidence base required to proceed to a larger randomized controlled trial (ORBIT Phase III).
Detailed description
Background.
Migraine affects approximately 1.04 billion individuals worldwide and is associated with substantial socioeconomic burdens, including reduced quality of life, mental health comorbidities (anxiety, depression), and productivity losses. Non-pharmacological interventions, including clinical hypnosis, represent a growing area of investigation.
Intervention.
The HYlaMI program consists of 8 weekly one-hour group sessions delivered via teleconference (Zoom, CIUSSS EMTL platform). Seven hypnotic exercises are introduced sequentially, each following a standard hypnotic structure (induction, deepening, hypnotic work, post-hypnotic suggestions, return to waking state):
- Session 1: Psychoeducation on medical hypnosis and pain + "Pleasant place" exercise
- Session 2: "Backpack" exercise (anxiety and emotion management)
- Session 3: "Doing nothing" exercise (pain acceptance, catastrophizing)
- Session 4: "Thermal object" exercise (pain perception modification)
- Session 5: "Magic hand" exercise (analgesic suggestion)
- Session 6: "Rossi method" (resource-based pain relief)
- Session 7: "Reconnecting with a resource" (introspection and self-efficacy)
- Session 8: Conclusion, self-hypnosis prescription and 30 minutes Focus group on Social Validity of the intervention
A 9th session (1h-Focus group on Self-hypnosis practice+ follow-up meeting) is held 4 weeks post-intervention.
All 7 hypnotic exercises are provided as high-quality audio recordings to enable home self-hypnosis practice between sessions.
Study Design
Mixed-methods pilot and proof-of-concept study with two parallel arms: HYlaMI intervention group and waitlist control group. Randomization is performed using an online random group generator. For ethical reasons, waitlist participants will receive the full intervention after study completion.
Outcome Assessment Schedule
14 measurement time points are planned: T-1 and T0 (pre-intervention baseline), T1-T8 (weekly during intervention), and T9-T12 (weekly post-intervention follow-up).
Hypnotizability
Baseline hypnotizability is assessed using the Harvard Group Scale of Hypnotic Susceptibility, Form A (HGSHS:A), French online version, and will be used as a covariate in all analyses.
Data Management
Electronic questionnaires are managed via REDCap (CIUSSS EMTL server). Paper journals are used for in-session measures. Focus groups are recorded via Zoom, transcribed using OneDrive Word, and analyzed with NVivo 12.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Waitlist control group | No intervention | –Participants assigned to the waitlist control group do not receive the HYlaMI intervention during the study period. They complete the same electronic questionnaires and weekly migraine diaries as the intervention group. For ethical reasons, they will receive the full HYlaMI intervention after study completion. |
| HYlaMI Intervention Group | Experimental | Behavioral: HYlaMI (Self-Hypnosis Training for Migraine Management)Participants assigned to the HYlaMI group attend 8 weekly group telehealth sessions and practice self-hypnosis at home using provided audio recordings. They complete paper journals (in-session EVA ratings and qualitative feedback), weekly electronic migraine diaries, weekly self-hypnosis practice logs, and all standardized questionnaires at designated time points. They participate in two semi-structured focus groups (T8 and T12). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Formal diagnosis of migraine for more than one year (physician-issued; self-reported diagnosis accepted)
- French-speaking
- No consumption of alcohol or recreational drugs on the morning before group hypnosis sessions (migraine rescue medication is accepted but must be reported if taken before a session)
- Reliable internet connection
- Available to follow the 2.5-month self-hypnosis training program
Key exclusion criteria (4 listed)
- Sensory or cognitive impairments that would interfere with comprehension (e.g., deafness)
- Severe, unstabilized neurological or psychiatric disorder that impairs communication
- Previous psychological treatment using hypnosis techniques for pain management
- Current participation in another psychological intervention (potential confounder for anxiety/depression outcomes)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HYlaMI (Self-Hypnosis Training for Migraine Management)Also: Self-hypnosis training; autohypnosis; HYlaDO adaptation for migraineEight weekly one-hour group telehealth sessions (Zoom/CIUSSS EMTL platform) delivering 7 complementary self-hypnosis exercises targeting migraine-related pain, stress, anxiety, and psychological resources. Each session follows a standardized hypnotic structure. High-quality audio recordings of all exercises are provided to participants for home self-hypnosis practice. A clinician-researcher (doctoral candidate in neuropsychology, trained in hypnosis) leads all sessions using a standardized clinician manual. A concluding focus group and follow-up session is held 4 weeks post-intervention. | Behavioural | HYlaMI Intervention Group |
Primary outcome
Migraine-related disability - Migraine Disability Assessment (MIDAS)
Time frame: One-week-pre-intervention (T0) and 4-week post-intervention follow-up (4-weeks-post-intervention: T12)
5-item scale quantifying the number of days affected by migraine in the past 3 months, generating a disability grade (I-IV). Clinically significant improvement defined as a reduction of ≥5 points (grade III, initial score 11-20) or ≥30% (grade IV, initial score >20), per American Headache Society (2019) criteria.
Migraine-related disability - Headache Impact Test (HIT-6)
Time frame: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
6-item scale (score range 36-78) assessing headache impact on daily functioning. Clinically significant improvement defined as a reduction of ≥5 points, per American Headache Society (2019) criteria.
Program feasibility - Retention and adherence rates
Time frame: Throughout intervention (first to 8th week of intervention: T1-T8)
Descriptive analysis of session attendance (target: ≥6/8 sessions) and attrition rate (target: ≤15%), based on the HYlaDO pilot study.
13 secondary outcomes
Anxiety and depressive symptoms
Time frame: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Pain self-efficacy
Time frame: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Situational pain
Time frame: Before and after each hypnosis session (First to 7th week of intervention : T1-T7)
Situational anxiety
Time frame: Before and after each hypnosis session (First to 7th week of intervention : T1-T7)
Situational relaxation
Time frame: Before and after each hypnosis session (First to 7th week of intervention: T1-T7)
Migraine frequency
Time frame: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12 )
Measure: Migraine intensity
Time frame: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Migraine duration
Time frame: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Medication intake
Time frame: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Work/school absenteeism
Time frame: Weekly (2-weeks-pre-intervention to 4-weeks-post-intervention: T-1 to T12)
Quality of life economics
Time frame: One-week-pre-intervention (T0), mid-intervention (week 4: T4), end of intervention (week 8: T8), and 4-week follow-up (4-weeks-post-intervention: T12)
Economic burden of migraine
Time frame: 6th week of intervention and 4-weeks-post-intervention follow-up (T6, T12)
Program improvement
Time frame: T8 (end of intervention) and T12 (4-week follow-up)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Migraine Disorder
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HYlaMI (Self-Hypnosis Training for Migraine Management) in people with Migraine Disorder, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David Ogez, PhD (+1 514 252-3400 ext. 4443, david.ogez@umontreal.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Migraine-related disability - Migraine Disability Assessment (MIDAS) (time frame: One-week-pre-intervention (T0) and 4-week post-intervention follow-up (4-weeks-post-intervention: T12)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.